Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•30/07/2026•06:30 ET
0
Whiz Insights
* Mitapivat (PYRUKYND(®) and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025
* Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026
Get started
Create a free account to read the full story.